ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates Annual General Meeting of Shareholders to be held on

ProQR Announces Annual General Meeting of

Shareholders and Provides Leadership Updates

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 1, 2022 -- ProQR Therapeutics

N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies,

today announced that its 2022 Annual General Meeting of Shareholders will take place on Thursday, June 30, 2022 at 14:00 CET (08:00 EDT)

via videoconference (the "AGM").

The Company also announced the following updates to its leadership.

"I am pleased to be working alongside Ren , Gerard, and with

John in these capacities to execute on the strategy we set forth in April," said Daniel A. de Boer, Founder and CEO of ProQR Therapeutics.

"With the benefit of the collective experience from this team, including Ren 's corporate development focus, Gerard's

scientific leadership and RNA expertise, and leveraging John's experience in building Alnylam, we are driving our strategy of accelerating

our Axiomer RNA-base editing platform technology, and also focusing on a select pipeline of RNA therapies for inherited retinal diseases."

De Boer added, "We are extremely grateful for the leadership Smital

has provided to put us in a strong financial position to deliver on our commitment to advance RNA therapies for diseases with high unmet

need. I am pleased to continue working with her as she moves to transition from the Company at the end of 2022 and I want to thank her

for her tremendous contributions toward our mission during her tenure."

Annual General Meeting of Shareholders

All relevant documents and information for the AGM, including the notice

and agenda, are or will be made available in the "Investors & Media" section of ProQR's website (www.proqr.com)

under "Financial Information". The documents will also be made available on the SEC's website at www.sec.gov. Shareholders

that wish to attend the videoconference should register as described in the notice and agenda, after which they will receive login details

for the videoconference.

ProQR Therapeutics is dedicated to changing lives through the creation

of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer ,

which uses a cell's own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific single nucleotide edits

in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for genetic diseases.

Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All

statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as

"anticipate," "believe," "could," "estimate," "expect," "goal,"

"intend," "look forward to", "may," "plan," "potential," "predict,"

"project," "should," "will," "would" and similar expressions. Such forward-looking

statements include, but are not limited to, statements regarding the potential of our technologies and platforms (including

Axiomer ) statements regarding our pipeline of programs targeting inherited retinal dystrophies and our updated strategic plans

and the intended benefits thereof. Forward-looking statements are based on management's beliefs and assumptions and on

information available to management only as of the date of this press release. Our actual results could differ materially from those

anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other

factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on

Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical

trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted

by the ongoing COVID-19 pandemic; the likelihood of our clinical programs being executed on timelines provided and reliance on our

contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and

maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk

of supply interruption from a contract manufacturer; the potential for later data to alter initial and preliminary results of

early-stage clinical trials, including as a result of differences in the trial designs and protocols across different trials; the

unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate

and continue to advance and progress our clinical programs; the outcomes of our planned interactions with regulatory authorities;

the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of,

inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new

data are generated in research and development; our ability to maintain and service our loan facility with Pontifax and Kreos;

general business, operational, financial and accounting risks; and risks related to litigation and disputes with third parties.

Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we

assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as

ProQR Therapeutics N.V.